The goal of this project is to evaluate the potential for improving the performance of adeno-associated virus (AAV)-based gene therapy for ornithine transcarbamylase deficiency. Ornithine transcarbamylase deficiency (OTCD) is an inherited disorder of the mammalian urea cycle, with nearly half of affected children presenting with extremely elevated blood ammonia levels within the first week of life, and a complete lack of functioning ornithine transcarbamylase (OTC) protein. This elevation of ammonia causes severe intellectual and developmental deficits when not fatal. We have developed an optimal AAV vector called the clinical candidate that provides rapid (<1day) and robust (>5 times native at the highest doses tested) and prolonged (>7 months) expression of OTC. N-carbamylglutamate (NCG) is effective at increasing urea production in patients with other urea cycle and metabolic disorders. NCG simulates the production of carbamylphosphate (CP) which is synthesized from ammonia and bicarbonate. In this way, NCG helps reduce ammonia by increasing CP formation. CP is a substrate for OTC, so increasing OTC activity will help convert CP via the urea cycle to non-toxic urea that can be safely excreted.
The specific aims of this project are to 1)Show NCG will benefit a model of mild OTCD, 2) that NCG and AAV gene therapy can work together to keep ammonia levels low, and 3) long term treatment with NCG for addressing OTCD is safe. We will compare the effects of treatment with or without NCG in mouse models of mild OTCD and complete OTCD to show that NCG in combination with AAV gene therapy has therapeutic benefit by measuring increased resistance to circulating levels of ammonia, normalization of blood and tissue metabolites, and absence of markers of liver injury. We expect that gene therapy will result in patients that have their outcome improved from having complete OTCD to a milder partial OTCD. NCG treatment is expected to provide increased cognitive protection by further aiding in the removal of ammonia. Having both an effective AAV candidate and an effective pharmacological reagent puts us in a unique position to be able to test this type of innovative combination therapy. This project uses a metabolic engineering approach to study a complex system affecting multiple organs, and methods are readily translatable to other systems biology questions, and the goal is to establish a model of possible clinical treatment. The significance is that keeping blood ammonia levels low in patients with OTCD is an essential part of protecting against developmental deficits.
The goal of this program is to further improve the performance of ornithine transcarbamylase gene therapy by using a pharmacological agent that increases the availability of one ofthe substrates that is needed. The experiments focus on showing the effectiveness of this drug in improving urea production in animal models with ornithine transcarbamylase deficiency.
|Ashley, Scott N; Somanathan, Suryanarayan; Hinderer, Christian et al. (2017) Alternative Start Sites Downstream of Non-Sense Mutations Drive Antigen Presentation and Tolerance Induction to C-Terminal Epitopes. J Immunol 198:4581-4587|
|Wang, Lili; Bell, Peter; Morizono, Hiroki et al. (2017) AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. Mol Genet Metab 120:299-305|
|Yang, Yang; Wang, Lili; Bell, Peter et al. (2016) A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol 34:334-8|
|Wang, Lili; Bell, Peter; Somanathan, Suryanarayan et al. (2015) Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol Ther 23:1877-87|
|Bissig-Choisat, Beatrice; Wang, Lili; Legras, Xavier et al. (2015) Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat Commun 6:7339|
|Mays, Lauren E; Wang, Lili; Lin, Jianping et al. (2014) AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. Mol Ther 22:28-41|
|Mikals, Kyle; Nam, Hyun-Joo; Van Vliet, Kim et al. (2014) The structure of AAVrh32.33, a novel gene delivery vector. J Struct Biol 186:308-17|
|Bryant, Laura M; Christopher, Devin M; Giles, April R et al. (2013) Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 24:55-64|
|Zhong, Li; Malani, Nirav; Li, Mengxin et al. (2013) Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. Hum Gene Ther 24:520-5|
|Wilson, James M; Shchelochkov, Oleg A; Gallagher, Renata C et al. (2012) Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. Mol Genet Metab 105:263-5|
Showing the most recent 10 out of 25 publications